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Biogenic amines are a collection of endogenous molecules that play pivotal roles as
neurotransmitters and hormones. In addition to the “classical” biogenic amines resulting
from decarboxylation of aromatic acids, including dopamine (DA), norepinephrine,
epinephrine, serotonin (5-HT), and histamine, other biogenic amines, present at much
lower concentrations in the central nervous system (CNS), and hence referred to
as “trace” amines (TAs), are now recognized to play significant neurophysiological
and behavioral functions. At the turn of the century, the discovery of the trace
amine-associated receptor 1 (TAAR1), a phylogenetically conserved G protein-coupled
receptor that is responsive to both TAs, such as β-phenylethylamine, octopamine,
and tyramine, and structurally-related amphetamines, unveiled mechanisms of action
for TAs other than interference with aminergic pathways, laying the foundations for
deciphering the functional significance of TAs and its mammalian CNS receptor, TAAR1.
Although, its molecular interactions and downstream targets have not been fully
elucidated, TAAR1 activation triggers accumulation of intracellular cAMP, modulates
PKA and PKC signaling and interferes with the β-arrestin2-dependent pathway via
G protein-independent mechanisms. TAAR1 is uniquely positioned to exert direct
control over DA and 5-HT neuronal firing and release, which has profound implications
for understanding the pathophysiology of, and therefore designing more efficacious
therapeutic interventions for, a range of neuropsychiatric disorders that involve aminergic
dysregulation, including Parkinson’s disease, schizophrenia, mood disorders, and
addiction. Indeed, the recent development of novel pharmacological tools targeting
TAAR1 has uncovered the remarkable potential of TAAR1-based medications as
new generation pharmacotherapies in neuropsychiatry. This review summarizes recent
developments in the study of TAs and TAAR1, their intricate neurochemistry and
pharmacology, and their relevance for neurodegenerative and neuropsychiatric disease.
Keywords: trace amines, trace amine-associated receptor 1, Parkinson’s disease, schizophrenia, mood disorders,
addiction
Pei et al. TAAR1 Neuropharmacology and Neuropsychiatry
INTRODUCTION
The classic biogenic amines, including dopamine (DA),
norepinephrine, epinephrine, serotonin (5-HT), and histamine,
are neurotransmitters that play vital roles in the regulation of
a wide variety of neurophysiological, behavioral, and cognitive
processes such as motor control, affect, motivation, learning,
and memory. Alterations in aminergic transmission have
been extensively documented in a broad range of neurological
disorders including Parkinson’s disease (PD), schizophrenia,
attention deficient hyperactivity disorder (ADHD), depression
and drug addiction, amongst others. Accordingly, the mainstay
pharmacological approach to the treatment for such conditions
has by and large relied on directly altering neurotransmission
of these classic monoamines. However, limited success has been
achieved thus far in the symptomatic relief in these disorders,
with direct manipulation of such neurotransmitter systems
being in some instances associated with untoward side effects.
In this regard, the DA system is a prototypical example. Chronic
L-DOPA treatment remains superior to other DA receptor
agonist-based interventions as symptomatic treatment for
PD but leads to long-term, debilitating motor complications
such as on-off fluctuations and dyskinesias (Kostic et al., 1991;
Fahn, 2000; Fabbrini et al., 2007; Kalia et al., 2013). Similarly,
neuroleptics, which are used for the treatment of psychotic and
bipolar disorder symptomatology, can cause extrapyramidal side-
effects characterized by acute dystonia, akathisia, parkinsonism,
and tardive dyskinesia (Ghaemi et al., 2006; Gao et al., 2008).
Moreover, the DA transporter (DAT) has long been targeted to
develop substitution treatments for drug addiction. However,
progress has been hindered by the potential abuse liability and
non-specific effects associated with replacement medications
based on DAT pharmacology, although promising results with
long-acting compounds have been reported (Desai et al., 2005;
Rothman et al., 2008; Ferragud et al., 2009; Tanda et al., 2009a,b;
Velazquez-Sanchez et al., 2009, 2010; Velázquez-Sánchez et al.,
2013; Reith et al., 2015). During the on-going search for more
efficacious medications in neuropsychiatry, the trace amine (TA)
transmitter system, a secondary amine system that is intimately
related to the classic biogenic amines, has attracted increasing
attention in recent years. TAs belong to a group of endogenous
amines whose neurobiological functions were largely neglected
until the breakthrough discovery of a group of G protein-
coupled receptors (GPCRs), the so-called trace amine-associated
receptors (TAARs), by two independent research groups in
2001 (Borowsky et al., 2001; Bunzow et al., 2001). Research
conducted in the past 15 years has concentrated primarily on
TAAR1, as the only member of this family of receptors that is
both responsive to TAs and phylogenetically conserved in the
mammalian brain (Borowsky et al., 2001; Lindemann et al.,
2005). TAAR1 has proved to be an important modulator of
the major biogenic amines and has begun to gain accumulated
support as a promising target for medicinal development in a
variety of neuropsychiatric disorders. In the current review we
summarize the latest advancements in understanding the role of
the TA system in the mammalian central nervous system (CNS),
focusing on its pharmacology and neurochemistry and on the
important implications of TAAR1 in the pathophysiology and
treatment of neuropsychiatric disorders that involve aminergic
dysregulation.
TRACE AMINES
TAs, including ρ-tyramine, m-tyramine, β-phenylethylamine
(β-PEA), m-octopamine, ρ-octopamine, tryptamine, and
synephrine are a group of endogenous amines found in both
invertebrate and vertebrate species (Berry, 2004). TAs have well-
documented roles in invertebrates as major neurotransmitters,
with octopamine believed to be the sympathetic nervous
system counterpart of norepinephrine in vertebrates (Robertson
and Juorio, 1976; Evans and O’Shea, 1977; Roeder, 1999). By
contrast, although the existence of TAs in the vertebrate brain
and peripheral nervous system has long been recognized, their
functions were largely unknown due to the apparent lack of
identified receptors specific for TAs, which prompted their
description as “false neurotransmitters” (Berry, 2004). TAs
are structurally similar to, and share same biosynthetic and
metabolic pathways with, the classic monoamines (Berry, 2004;
Ledonne et al., 2011). Initial studies postulated that TAs exerted
sympathomimetic actions in the vertebrate peripheral nervous
system, linking them to blood pressure regulation and electrolyte
homeostasis (Barger and Dale, 1910; Podder et al., 1979). This
notion can be traced back to the clinical observation of the
so-called “cheese reaction,” a hypertensive crisis experienced
by sensitive patients treated with monoamine oxidase (MAO)
inhibitor class of antidepressant drugs and exposed to aged
cheese and other types of processed food enriched in ρ-
tyramine produced through bacteria decarboxylation during
fermentation (Blackwell and Mabbitt, 1965; Boulton et al.,
1970; Rice et al., 1976; Stratton et al., 1991; Anderson et al.,
1993). It has been shown that peripheral tyramine releases
endogenous norepinephrine from peripheral stores, which in
turn stimulates adrenergic nerves, a process responsible for its
indirect sympathetic action (Crout et al., 1962; Tapper et al.,
1981).
In the CNS, TAs are present at low nanomolar concentrations
at a range that is several hundred-fold below that of the classical
neurotransmitters, which can be linked to their extremely
rapid turnover rate and a very short half-life of around
30 s (Burden and Philips, 1980; Berry, 2004). TAs exhibit
a heterogeneous distribution that closely parallels the classic
monoaminergic projection pathways, with enhanced expression
in the nigrostriatal and mesolimbic dopaminergic pathways
(Philips, 1984). Evidence suggests that some TAs, including
ρ-tyramine, β-PEA, and tryptamine, are synthesized within
nigrostriatal DA neurons while ρ-octopamine is synthesized
within adrenergic neurons (Berry, 2004). However, as indicated
previously, TAs were regarded for a considerable time as
mere metabolic by-products of other neurotransmitters and
having little neurophysiological significance in their own right.
In subsequent studies, TAs were classified as endogenous
neuromodulators that regulated, and were themselves susceptible
to regulation by, co-existing neurotransmitters (Berry, 2004).
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Indeed, ample evidence has demonstrated an intimate functional
inter-regulation between TAs and the classic monoamines,
especially DA. First, changes in monoamine activity are able
to alter TA levels. For example, while reductions in striatal
levels of β-PEA (Juorio et al., 1991) and ρ-tyramine (Jones
et al., 1983) were found to increase DA release triggered by
electrical stimulation of the substantia nigra, inhibition of DA
neurotransmission led to an elevated accumulation rate of β-
PEA in the striatum (Juorio et al., 1991). Reciprocally, TAs
appeared to potentiate the efficacy of synaptic transmission
mediated by these monoamines (Philips, 1984; Burchett and
Hicks, 2006). For instance, administration of MAO-B inhibitors,
which increased β-PEA levels above their physiological range,
enhanced the striatal neuronal response to DA (Berry et al., 1994)
and DA agonists (Paterson et al., 1991). Moreover, iontophoretic
application of β-PEA elicited a potentiated cortical neuronal
response to norepinephrine (Paterson and Boulton, 1988;
Paterson, 1993). Similarly, iontophoretic ejection of ρ-tyramine,
m-tyramine, and β-PEA applied at weak currents increased the
cortical neuronal response to DA (Jones and Boulton, 1980).
Likewise, application of octopamine through weak iontophoretic
currents enhanced both inhibitory and excitatory neuronal
response mediated by norepinephrine (Jones, 1982a). The effect
of tryptamine on 5-HT neurotransmission appeared to be more
complex as both a depression and potentiation of 5-HT-mediated
neuronal effects were observed, which might be accounted for
by the biphasic effects of 5-HT itself on cortical neuron activity
(Jones, 1982b). Taken together, these findings suggest that TAs
are likely to serve as a fine-tuning mechanism that keeps a
balanced monoaminergic tone by responding to endogenous- or
exogenous-induced monoamine fluctuations, a process that may
be partly mediated through interaction with specific receptors for
TAs (Berry, 2004).
Given the abovementioned reciprocal relationship between
TAs and monoamines, it is not surprising that dysfunction of TA
signaling has been historically associated with an ample spectrum
of neurological pathologies that involve changes in monoamine
function. For example, a reduced level of urinary excretion
of β-PEA was found in children with ADHD (Baker et al.,
1991). Moreover, while deficient synthesis of two TAs, tyramine,
and octopamine (Sandler et al., 1979), and decreased urinary
excretion of β-PEA (Wolf and Mosnaim, 1983), have been
found in patients with depressive disorders, PEA replacement
treatment produced long-lasting relief of depression in a patient
population (Sabelli et al., 1995). Furthermore, women with
bipolar affective disorder show very high rate of urinary β-PEA
excretion whilst MAO inhibitors, which further increased β-PEA
excretion, exacerbated their symptoms (Karoum et al., 1982).
In addition, chronic treatment with the psychotogenic drugs,
lysergic acid diethylamide (LSD) and phencyclidine, produced
upregulation of aromatic L-amino acid decarboxylase (AADC,
an enzyme that catalyses the synthesis of β-PEA) mRNA levels,
indicating that over-production of β-PEA may be involved
in the pathogenesis of psychotic syndromes (Buckland et al.,
1997). Indeed, urinary β-PEA level was found to be significantly
elevated in paranoid chronic schizophrenics (Potkin et al.,
1979).
TAs have also been implicated in the action of
psychostimulants and, more widely, in drug addiction. For
example, β-PEA bears close structural and pharmacological
similarity with the central stimulant, amphetamine (Tinklenberg
et al., 1978; Janssen et al., 1999). At concentrations that were
several orders of magnitude above its normal physiological
range, β-PEA induced amphetamine-like effects in rodents
and monkeys, including hyperactivity (Dourish, 1985) and
stereotypic behavior (Borison et al., 1977; Tinklenberg et al.,
1978). This evidence led to the characterization of β-PEA
as brain “endogenous amphetamine” (Janssen et al., 1999).
Moreover, β-PEA activity is altered by exogenous application of
d-amphetamine. Acute application of d-amphetamine resulted
in an initial decrease and a subsequent increase in brain
level of β-PEA in rabbits (Borison et al., 1975). Also, chronic
administration of amphetamine in rats downregulated AADC
mRNA levels, which could in turn lead to decreased β-PEA
activity (Buckland et al., 1996). On the other hand, certain
behavioral effects of amphetamine appeared to be dependent
on β-PEA levels as depletion of brain β-PEA blocked the
motor-stimulating effect of d-amphetamine in mice and rabbits
(Borison et al., 1975).
Furthermore, evidence has accrued on the ability of TAs
to modulate brain reward (i.e., the subjective experience
of pleasure) and reinforcement (i.e., the strengthening of a
conditioned response by a given stimulus; Greenshaw, 1984),
suggesting the involvement of the TAs in the neurological
adaptations underlying drug addiction, a chronic relapsing
syndrome characterized by compulsive drug taking, inability to
control drug intake and dysphoria when access to the drug is
prevented (Koob, 2009). Consistent with its hypothesized role
as “endogenous amphetamine,” β-PEA was shown to possess
reinforcing properties, a defining feature that underlies the abuse
liability of amphetamine and other psychomotor stimulants.
β-PEA was also as effective as amphetamine in its ability to
produce conditioned place preference (i.e., the process by which
an organism learns an association between drug effects and
a particular place or context) in rats (Gilbert and Cooper,
1983) and was readily self-administered by dogs that had a
stable history (i.e., consisting of early acquisition and later
maintenance) of amphetamine or cocaine self-administration
(Risner and Jones, 1977; Shannon and Thompson, 1984). In
another study, high concentrations of β-PEA dose-dependently
maintained responding in monkeys that were previously
trained to self-administer cocaine, and pretreatment with a
MAO-B inhibitor, which delayed β-PEA deactivation, further
increased response rates (Bergman et al., 2001). However,
other studies have revealed an opposing action of TAs on
brain reward. In rats that responded at threshold levels for
intracranial self-stimulation (ICSS) of the lateral hypothalamus,
tryptamine antagonists not only caused dose-related increases
when given alone but also potentiated the facilitating effects
of amphetamine (Silveira Filho and Graeff, 1977). Conversely,
systematic application of tryptamine decreased intracranial self-
stimulation (ICSS) in both the medial raphe nucleus and
the lateral hypothalamus (Broadbent and Greenshaw, 1985).
These findings suggest an inhibitory regulation of brain reward
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processing via the tryptamine-mediated pathway. Also, in sharp
contrast to the conditioned place preference produced by β-PEA,
as noted above, tryptamine induced conditioned taste aversion to
a novel saccharin solution in rats (Fletcher, 1986), suggesting a
negative influence on reward-related behavior. Moreover, while
little is known about the role of octopamine in brain reward
in vertebrates, the functional contribution of octopamine to
reward-associated learning has been well-documented in insects
(Hammer, 1997; Unoki et al., 2006; Perry and Barron, 2013).
Studies conducted inDrosophila suggest that tyramine is essential
for the development of cocaine sensitization (McClung and
Hirsh, 1999), a phenomenon thought to share similar underlying
neuroadaptive mechanisms to those mediating craving and
relapse (Kalivas et al., 1998).
Although these findings have underscored the implication of
TAs in key behavioral and neurological functions, the signaling
mechanisms and downstreammolecular targets to which they are
coupled have remained unclear until recently. For a considerable
time, the prevailing view regarding the mode of action of TAs
held two possible routes of action (Sotnikova et al., 2004; Burchett
and Hicks, 2006). First, it was suggested that TAs interact with
plasma membrane transporters to inhibit monoamine uptake
and induce eﬄux through reverse transport or interfere with
monoamine vesicular storage to displace the classic monoamines
from their storage pool (Raiteri et al., 1977; Parker and
Cubeddu, 1988). Second, TAs could bind to yet unidentified
TA-sensitive signaling proteins located on pre- or post-synaptic
neurons containing GPCRs for the classic monoamines, thereby
modulating their corresponding intracellular second messenger
pathways (Premont et al., 2001; Sotnikova et al., 2004; Burchett
and Hicks, 2006). Moreover, in addition to altering the major
aminergic pathways, TAs have been shown to modulate neuronal
signaling mediated by other important neurotransmitters, such
as gamma-aminobutyric acid (GABA; Berretta et al., 2005;
Federici et al., 2005) and acetylcholine (Kato et al., 2001; Ishida
et al., 2005), but the functional relevance of such interactions is
not well-understood at present.
IDENTIFICATION OF TAAR FAMILY
Progress in the characterization of the neurobiological functions
of TAs has been hampered by the difficulty in identifying their
specific receptor targets and the lack of selective agonists and
antagonists for such receptors. Although, saturable high-affinity
binding sites distinct from the amine transporters and receptors
had been identified in the mammalian brain (Kellar and Cascio,
1982; Brüning and Rommelspacher, 1984; McCormack et al.,
1986; Nguyen and Juorio, 1989), it was at the beginning of
the twenty-first century that two research groups independently
reported the cloning and identification of a novel family of
mammalian GPCRs (Borowsky et al., 2001; Bunzow et al., 2001).
Such receptors, including several orphan receptors, shared an
unusually high degree of sequence homology and some were
directly activated by TAs. The discovery of receptors for TAs
supported their role as bona fide neurotransmitters, this is, as
molecules able to trigger cellular events directly, and led to a
renewed interest in the TAs and their biological functions. In
subsequent studies, Lindemann and collaborators proposed a
uniform nomenclature for this newly discovered GPCR family,
together with closely related receptors, as trace-amine-associated
receptors (TAARs), acknowledging the fact that some members
are unresponsive to TAs (Lindemann et al., 2005). Further,
work by the same group completed the identification of all
members of this GPCR family in rats, mice, chimpanzees, and
humans, demonstrating remarkable differences in the number
of receptor genes and the proportion of pseudogenes amongst
the four species (Lindemann et al., 2005). There are nine TAAR
genes in human including three pseudogenes; nine genes in
chimpanzee including six pseudogenes; 19 and 16 in rat and
mouse with two and one being pseudogenes, respectively. In
spite of these significant inter-species differences, three TAAR
subfamilies were identified based on phylogenetic relationships
and pharmacophore similarities, which remained consistent
across all of the four species (Lindemann et al., 2005). The three
subfamilies consist of TAARs 1–4, TAAR5, and TAARs 6–9, with
each subgroup represented by at least one functional TAAR gene.
Not surprisingly, the only two receptors that are activated by TAs,
namely TAAR1 and TAAR4, both belong to the first subfamily,
supporting a functional basis for the classification (Lindemann
et al., 2005). While TAAR1 is sensitive to all TAs and the TAAR1
gene is phylogenetically conserved in all the studied species
including human, TAAR4 is a pseudogene in the human genome
and rat TAAR4 responds only to β-PEA and tyramine, although
to a much lesser degree than TAAR1 (Borowsky et al., 2001;
Bunzow et al., 2001; Lindemann et al., 2005). As a result, TAAR1
has received by far the most attention over the past decade and
it is the best characterized receptor of the class (Lindemann and
Hoener, 2005).
EXPRESSION, SIGNALING, AND
PHARMACOLOGY OF TAAR1
TAAR1 couples to a Gαs G protein and, upon stimulation,
triggers accumulation of intracellular cAMP via adenylyl cyclase
activation and stimulates inwardly rectifying K+ channels
(Borowsky et al., 2001; Bunzow et al., 2001; Miller et al., 2005;
Xie et al., 2007; Bradaia et al., 2009). TAAR1 activation can
also lead to PKA and PKC phosphorylation and upregulation
of the transcription factors, CREB and NFAT (Panas et al.,
2012). TAAR1 also signals via a G-protein independent, β-
arrestin2-dependent pathway involving the protein kinase B
(AKT)/glycogen synthase kinase 3 (GSK-3) β signaling cascade,
an important player in many DA-mediated actions (Harmeier
et al., 2015; Figure 1). Among the TAs, β-PEA and tyramine
are the most potent activators at TAAR1, with β-PEA being
more potent than tyramine at human and mouse TAAR1, with
the opposite being true at rat TAAR1 (Bunzow et al., 2001;
Grandy, 2007; Wainscott et al., 2007). Strikingly, in addition
to TAs as principal binding ligands, TAAR1 is also activated
by a vast variety of endogenous and exogenous molecules,
including the major catecholamines, DA, norepinephrine, and 5-
HT and some of theirmetabolites, amphetamine-like compounds
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FIGURE 1 | Trace amine-associated receptor 1 (TAAR1), a TA- and amphetamine-activated GPCR, at a DA synapse. Amphetamines enter the presynaptic
neurons through competitive reuptake inhibition of the DA transporter (DAT) and by diffusion through presynaptic membranes, causing release of DA by way of
vesicular monoamine transporter-mediated exocytosis and reverse transport through the DAT. Both amphetamines and endogenous TAs activate TAAR1, leading to
adenylyl cyclase (AC) activation and downstream stimulation of PKA/PKC. Like D2R, TAAR1 also signals via a G-protein independent, β-arrestin2-dependent pathway
involving the protein kinase B (AKT)/glycogen synthase kinase 3 (GSK-3) β signaling cascade. In the case of striatal D2R, β-arrestin 2 has been shown to enhance the
interaction between AKT and protein phosphatase 2A thereby resulting in AKT inactivation and increased activation of GSK-3. D2s are also GPCRs which when
attached to TAAR1 form heterodimeric complexes. Interaction of TAAR1 with D2R reduces β-arrestin 2 recruitment to D2R and the ability of D2R to decrease cAMP
production, whereas β-arrestin 2 signaling is enhanced, resulting in reduced GSK-3 activation. In addition, phosphorylation of the DAT through TAAR1-stimulated
activation has been shown to lead to DAT internalization, which may result in reduced DA uptake under certain conditions.
including amphetamine itself, methamphetamine and 3,4-
methylenedioxymethamphetamine (MDMA), ergot derivatives
including LSD, and several adrenergic ligands (Bunzow et al.,
2001), as well as certain thyroid hormones derivatives (Hart et al.,
2006). Studies aiming at determining TAAR1 distribution in
the mammalian system have consistently reported a widespread
and unique pattern of TAAR1 mRNA or protein expression in
the central and peripheral nervous system in human, mouse,
rat, and rhesus monkey. In the brain, TAAR1 mRNA has
been detected throughout the limbic system and in regions
associated with the major monoaminergic pathways, including
the ventral tegmental area (VTA), substantia nigra (SNr), locus
coeruleus, raphe nucleus, caudate nucleus, putamen, nucleus
accumbens (NAc), hippocampus, hypothalamus, and amygdala
(Borowsky et al., 2001; Bunzow et al., 2001; Miller et al., 2005;
Xie et al., 2007; Lindemann et al., 2008; Espinoza et al., 2015). In
addition to subcortical areas, TAAR1 is also expressed in cortical
regions, especially in layer V pyramidal neurons of the prefrontal
cortex (PFC; Espinoza et al., 2015). The cellular distribution of
TAAR1 is predominantly intracellular, with diffuse expression
within the perikaryon and along axonal processes, and sparse
membrane-associated neuronal expression (Bunzow et al., 2001;
Xie et al., 2007). Therefore, it has been postulated that the
intracellular TAAR1 might recruit an accessory protein for
translocation to the plasma membrane (Bunzow et al., 2001)
or indeed might signal intracellularly, given the accessibility
of several TAAR1 endogenous ligands within the cytoplasm
and the ability of intracellular GPCRs to exert downstream
effects (Xie et al., 2007; Lam et al., 2015). Remarkably, TAAR1
is colocalized with DAT in a subset of DA neurons, and/or
expressed in neurons that are in close apposition to DAT-
expressing neurons inmouse and rhesusmonkey substantia nigra
(Xie et al., 2007). There is also evidence suggesting co-expression
of TAAR1 with the norepinephrine transporter in adrenergic
neurons in the rhesus monkey locus coeruleus, as well as co-
localization with 5-HT transporter in serotonergic neurons in
the mouse dorsal raphe nucleus (Lindemann et al., 2008; Xie
et al., 2008). The neuroanatomical distribution of TAAR1 in
relation to the major monoamine systems suggests that TAAR1
might be in a position to regulate monoaminergic transmission
through direct interactions with monoamine transporters and
presynaptic autoreceptors co-expressed with TAAR1 within
single neurons, or by way of intercellular communication with
nearby monoaminergic neurons. In the next section we will
review evidence from different research lines in support of such
fundamental neurochemical interactions.
FUNCTIONAL INTERACTION OF TAAR1
WITH BRAIN MONOAMINE SYSTEMS
Studies with heterologous expression systems and brain
synaptosomes have revealed a complex tripartite relationship
between TAAR1, monoamine transporters, and monoamine
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autoreceptors in vitro. First, in such in vitro preparations, TAAR1
activation by agonist ligands, including TAs, the classic biogenic
amines, and drugs of the amphetamine-class, was shown to be
markedly enhanced by co-transfecting TAAR1 with monoamine
transporters (Miller et al., 2005; Xie et al., 2007). Since, these
TAAR1 agonists are also substrates at monoamine transporters,
it has been hypothesized that the monoamine transporters might
serve as conduits for the entry of TAAR1 agonists into the
synaptic terminal such that activation of intracellular TAAR1
can occur (Miller et al., 2005; Xie et al., 2007; Miller, 2011).
Alternatively, the transporter-mediated agonist uptake might
trigger trafficking of TAAR1 into the plasma membrane (Xie
et al., 2007). Additionally, such in vitro assays have revealed
that TAAR1 activation functionally downregulates the activity
of monoamine transporters. In cells co-transfected with both
TAAR1 and one of the main aminergic transporters, TAAR1
activation by DA, norepinephrine or 5-HT led to functional
inhibition of the co-expressed transporter, reducing uptake, and
increasing eﬄux of the associated neurotransmitter (Xie et al.,
2008).
Moreover, further evidence suggests that both TAAR1
and monoamine autoreceptor activation modulate monoamine
transporter function reciprocally by way of opposing interactions
on aminergic transmission (Xie et al., 2008). While TAAR1
activation promotes eﬄux of monoamines through their
transporter proteins, autoreceptor activation leads to increases
in the uptake of classical biogenic amines in monkey and
wild-type mouse striatal and thalamic synaptosomes, with this
effect being absent in synaptosomes from TAAR1 knockout
(KO) mouse (Xie et al., 2008). The same authors showed
that when the DA, norepinephrine and 5-HT transporters
were co-transfected with D2s, α2A, or 5-HT1B autoreceptors,
uptake of the respective amine transmitter was significantly
enhanced. Similarly, norepinephrine and 5-HT also reduced
retention of the preloaded neurotransmitter in the presence of the
specific autoreceptor antagonist in both monkey and wild-type
mouse, but not in TAAR1 KO, synaptosomes. TAAR1-dependent
monoamine eﬄux has been attributed to reversed transport of
monoamines through their corresponding transporters resulting
from TAAR1-mediated intracellular cAMP accumulation and
substrate phosphorylation (Xie et al., 2008). Together, these
findings indicate that the classical biogenic amines interact
with both TAAR1 and monoamine autoreceptors to regulate
transporter function. Thus, a concept of presynaptic receptor
balancing has been proposed whereby TAAR1 and monoamine
autoreceptors equilibrate monoamine activity, with the former
inhibiting uptake and the latter facilitating it (Xie et al., 2008; Xie
and Miller, 2009b).
More recent evidence from both in vitro and in vivo
studies suggests a direct interaction of TAAR1 with monoamine
autoreceptors that may underlie the presynaptic receptor
balancing previously proposed. First, TAAR1 and D2s receptors,
when co-expressed in cells, were able to form constitutive
heterodimers in plasma membrane, thus allowing functional
regulation of these two GPCR and/or other cellular substrates
(Espinoza et al., 2011). Indeed, both total and membrane
expression level of TAAR1 was decreased by co-expressing it with
D2s in the same cells (Espinoza et al., 2011). Such interactions
between TAAR1 and D2s receptors are in part mediated by
receptor heterodimerization. Previously, it was shown that co-
transfecting D2s, α2A, or α2B, or 5-HT1A or 5-HT1B along
with TAAR1 attenuated TAAR1 activation-induced intracellular
cAMP in response to DA, norepinephrine or 5-HT, respectively
(Xie et al., 2008). Thus, the facilitating effects of autoreceptor
activation on monoamine transporter function could result from
either direct enhancement or suppression of TAAR1-mediated
inhibition of transporter function. It is important to note that
more recent studies indicate that TAAR1 activation may also
potentiate D2s-mediated inhibition of monoamine transmission,
an effect that is lacking in TAAR1 KO mice (Leo et al., 2014).
Similarly, previous findings indicated that activating TAAR1
with specific agonists increased agonist potency at 5-HT1A
receptors whereas selective blockade of TAAR1 produced the
opposite effects (Revel et al., 2011). Collectively, these findings
suggest that TAAR1 stimulation may have dual effects on
monoaminergic activity. While TAAR1’s direct inhibition of the
monoamine transporter may result in extracellular monoamine
accumulation, TAAR1-mediated upregulation of monoamine
autoreceptors may lead to enhanced transporter function and
depressed monoamine transmission. However, it is important
to bear in mind that controversy exists as to the existence of
functional in vivo receptor couplings and caution should be taken
when assessing the findings on in vitro heterodimerization and its
functional consequences. For example, whilst hetero-oligomers
of G-protein-coupled receptors have become the subject of much
research due to their potential ability to signal differently from
their component receptors, which could have implications for
the development of novel pharmacotherapies, the identification
of such complexes in vivo has been challenging (Frederick et al.,
2015). Thus the validity of this approach needs to be carefully
considered.
Therefore, it would appear that the relative activation of
TAAR1 and D2s receptors by endogenous or exogenous ligands
critically determines the net output of monoaminergic systems
through key effects on transporter regulation (Xie and Miller,
2009b). Unlike the common biogenic amines, which activate
both types of receptors, the endogenous TAs are agonists at
TAAR1 only. Consequently, selective TAAR1 stimulation by TAs
or specific agonists is distinct from TAAR1 activation by classical
monoamines in that these trigger inhibitory modulation of
TAAR1 through autoreceptor co-stimulation. Not surprisingly,
in vitro, the co-expression of monoamine autoreceptors with
TAAR1 attenuated TAAR1 signaling in response to common
monoamines, but not to β-PEA (Xie and Miller, 2008). In
agreement with these findings, while the common biogenic
amines significantly enhanced uptake in cells co-transfected with
the respective monoamine autoreceptors and transporters, β-
PEA did not (Xie and Miller, 2008).
Further, accentuating the complexity of TAAR1 molecular
interactions atmonoamine synapses, recent studies have unveiled
regulatory effects of TAAR1 signaling on post-synaptic D2
receptors. While TAAR1 KO mice had impaired striatal
presynaptic D2s-mediated autoinhibition (Leo et al., 2014),
they also exhibited upregulation of striatal post-synaptic D2
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receptors mRNA and overactivity of D2 receptor-mediated
G protein/cAMP-independent, β-arrestin2-dependent signaling
pathway (Espinoza et al., 2015). D2 receptor activation through
β-arrestin2 has been shown to dephosphorylate AKT and its
downstream target GSK3β, leading to inhibited AKT activity
and subsequent increase in GSK3β signaling (Beaulieu et al.,
2011). Decreased phosphorylation of AKT with concomitant
elevation of GSK3β is associated with excessive dopaminergic
stimulation, as produced either by indirect DA agonists including
psychostimulants, such as amphetamine and cocaine, or by DAT
deletion (Beaulieu et al., 2004; Li and Gao, 2011). Conversely,
pharmacological or genetic inhibition of GSK3β reversed DA-
stimulated behaviors and reduced the effects of psychostimulants
(Beaulieu et al., 2004, 2005; Li and Gao, 2011). Therefore, the
finding that striatal D2 receptors and associated AKT/GSK3β
signaling pathway are upregulated in TAAR1 KO mice suggests
that TAAR1 activation may counteract DA signaling at post-
synaptic sites, although this effect is likely to be indirect.
A recent study reported that the formation of heteromeric
complexes between TAAR1 and D2 receptors not only reduces
TAAR1-stimulated cAMP accumulation, but also shifts β-
arrestin2 recruitment from activated D2 receptors to activated
TAAR1 (Harmeier et al., 2015). Thus this complementary
evidence suggests that TAAR1 may be able to downregulate DA
transmission not only by potentiating D2s-mediated presynaptic
autoinhibition but also through inhibiting D2 receptor-mediated
postsynaptic signaling. In support of this notion, mice with
TAAR1 depletion exhibited greater locomotor activity compared
to wild-type counterparts when challenged with quinpirole, a D2-
like receptor agonist that is known to inhibit locomotion at low
doses via stimulating presynaptic D2s and enhance locomotion
at high doses by activating post-synaptic D2-like receptors,
suggesting that TAAR1 deletion may induce super-sensitivity of
post-synaptic D2-like receptors (Espinoza et al., 2015).
Taken together, these findings suggest that multidirectional
interactions occur between TAAR1 and monoamine molecular
targets at both pre- and post-synaptic sites. However, knowledge
derived from evidence at cellular and molecular levels raises the
question as to the ultimate functional outcome of these complex
interactions and the exact neurophysiological role of TAAR1.
Inspection of the neurological and behavioral adaptations
exhibited by transgenic mice with TAAR1modifications provides
additional insight into this question. Compared to wild-type
littermates, TAAR1 KO mice exhibited no differences in general
health indicators as well as general motor function (Wolinsky
et al., 2007; Lindemann et al., 2008) but displayed deficits
in pre-pulse inhibition of acoustic startle, a DA-dependent
response, indicating impaired sensorimotor gating (Wolinsky
et al., 2007). Moreover, these KO mice had elevated spontaneous
firing frequency and depolarized resting membrane potential of
DA neurons in the VTA (Lindemann et al., 2008), amplified
spontaneous spike rate of 5-HT neurons in the dorsal raphe
nucleus (Revel et al., 2011), and increased extracellular DA in
the NAc (Leo et al., 2014). Likewise, they showed enhanced
sensitivity to amphetamine-induced locomotor activity and
increased extracellular DA, norepinephrine, and 5-HT levels in
the striatum (Wolinsky et al., 2007; Lindemann et al., 2008),
and methamphetamine-induced conditioned place preference
(Achat-Mendes et al., 2012). When challenged with MDMA
(“ecstasy”), the wild-type mice displayed dose-dependent,
biphasic thermoregulatory responses with early hypothermia
followed by hyperthermia, but TAAR1 KO mice only showed
long-lasting hyperthermia accompanied by supersensitivity to
MDMA-stimulated locomotor activity and release of DA and 5-
HT in the NAc and dorsal striatum, and of DA in the frontal
cortex (Di Cara et al., 2011).
By contrast, mice engineered to overexpress TAAR1 showed
unaltered spontaneous locomotor activity but hyposensitivity to
amphetamine-induced psychomotor activity and catecholamine
release in the NAc (Revel et al., 2012a). Taken together,
these findings suggest that TAAR1 may be constitutively
active or tonically activated by ambient levels of endogenous
amines to exert an inhibitory influence on monoaminergic
neurotransmission. Furthermore, these data suggest that TAAR1
activation may reduce the potentiation of monoaminergic
transmission elicited by motor stimulant drugs. TAAR1
activation by amphetamine, methamphetamine and MDMA,
which are themselves agonists at TAAR1, may reduce the
neurochemical and behavioral actions of these drugs (Lindemann
et al., 2008; Di Cara et al., 2011; Miller, 2011).
Studies with the most recently engineered highly selective
TAAR1 agonists and antagonists have provided more direct
evidence for TAAR1’s inhibitory influence on monoamine
transmission. The selective TAAR1 antagonist, EPPTB, increased
the firing rate of DA neurons in mouse VTA (Bradaia et al.,
2009), which is in agreement with the notion that TAAR1 is
constitutively active or tonically activated by ambient levels
of amines to downregulate DA activity. Moreover, while the
selective TAAR1 full agonists, RO5166017 and RO5256390,
decreased the firing frequency of DA neurons in the VTA
and of 5-HT neurons in the dorsal raphe nucleus, the partial
agonists, RO5203648 and RO5263397, enhanced the firing rate
of these same neurons, further suggesting high constitutive
activity or tonic activation of TAAR1, that serves to keep
monoamine transmission in balance. These findings have led
to the suggestion that pharmacological TAAR1 activation may
provide a means to modulate altered DA transmission in
pathophysiological states (Revel et al., 2011, 2012a, 2013).
Subsequent studies have reported findings in agreement with
this possibility. Whereas the full agonist, RO5166017, reduced
electrically evoked DA release in both the dorsal striatum
and NAc in slices of mouse brain, the antagonist, EPPTB,
increased NAc DA release (Leo et al., 2014). Further, the
partial agonist, RO5203648, prevented cocaine-induced DA-
overflow, in vitro, (Pei et al., 2014) and transiently attenuated
methamphetamine-induced DA accumulation in the NAc, in
vivo (Cotter et al., 2015), although it increased the firing
rate of DA neurons in the VTA under basal conditions. In
behavioral experiments, both full and partial agonists blocked the
hyperlocomotion induced by cocaine or amphetamine in wild-
type mice and mutant mice with genetic DAT deletion (Revel
et al., 2011, 2012a, 2013). Collectively, these findings strongly
support a role for TAAR1 as a regulator or stabilizer of the DA
system.
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TAAR1 LIGANDS AND IMPLICATIONS
The discovery of TAAR1 as a distinguishable binding site for
TAs not only supported the categorisation of TAs as bona
fide neurotransmitters but also unveiled a potential underlying
mechanism linking various neuropsychiatric disorders with
dysfunction of the TA system. As discussed above, TAAR1
activation by TAs can regulate monoamine transporter and
monoamine transmission, supporting TAAR1 as the action site
throughwhich TAs exert control on neurophysiological processes
(Xie and Miller, 2008). However, caution should be exerted
when attributing TAs’ effects to TAAR1 because routes of
action other than TAAR1 may also exist for TAs (Van Nguyen
et al., 1989; Vaccari, 1993; Borowsky et al., 2001). For example,
evidence has revealed that β-PEA and tyramine reversibly
reduced D2s autoreceptor-mediated G-protein-gated inward
rectifier K+ channel currents in mice midbrain DA neurons
by acting at sites other than TAAR1 (Ledonne et al., 2010).
Additionally, several by-products of catecholamine metabolism
exert actions at TAAR1. 3-methoxytyramine, normetanephrine,
and metanephrine, the meta-O-methyl metabolites of DA,
norepinephrine, and adrenaline, respectively, cause TAAR1-
stimulated cAMP elevations with significantly higher potencies
than those achieved by their parent catecholamine (e.g., 3-MT vs,
DA—2-fold; (±)NMN vs norepinephrine (0.1)—4-fold; (±)MN
vs. epinephrine—2.5-fold; Bunzow et al., 2001). Given that these
metabolites are generally considered as biologically inactive
degradation products, the discovery of their high binding affinity
at TAAR1 suggests that their importance may be greater than
previously recognized. Furthermore, the direct DA agonists
apomorphine and bromocriptine were found to activate TAAR1
in vitro (Bunzow et al., 2001). Although, the degree to which
their possible interaction with TAAR1 contributes to their
physiological and behavioral effects in vivo remains speculative,
recent evidence suggests that certain characteristic stereotypic
behaviors, such as climbing and licking, induced by high doses
of apomorphine, are at least partially mediated by TAAR1
(Sukhanov et al., 2014).
In view of the structural similarity between amphetamine-
like compounds and β-PEA, it is not surprising that
amphetamine and some amphetamine derivatives, including
methamphetamine, MDMA, and 2-amino, 1-[2,5-dimethoxy-4-
iodophenyl]-propane (DOI), are direct agonists at TAAR1. Their
ability to stimulate cAMP production has been consistently
reported at mouse, rat, rhesus monkey, and human TAAR1
expressed in various model cell systems, with potencies
comparable to, or slightly weaker than, β-PEA or tyramine,
although species differences and isomer-stereoselectivity in
agonistic potency and efficacy were also noticed (Bunzow et al.,
2001; Miller et al., 2005; Reese et al., 2007; Wainscott et al.,
2007; Barak et al., 2008). Drugs in the amphetamine-class are
well-known for their ability to increase extracellular levels of
monoamines in the brain mainly by acting as monoamine
transporter substrates, competing with monoamines for
reuptake, causing transporter internalization, and promoting
transporter-mediated eﬄux (reverse transport) (Khoshbouei
et al., 2003, 2004; Elliott and Beveridge, 2005; Han and
Gu, 2006). They also interfere with vesicular monoamine
transporter-2, depleting monoamine vesicular storage, and
increasing cytosolic monoamine availability for reverse transport
(Brown et al., 2002; Partilla et al., 2006; Lizarraga et al., 2015;
Freyberg et al., 2016). The potent DA-releasing capacity of
these psychostimulants critically underlies their reinforcing
properties and abuse liability (Marona-Lewicka et al., 1996;
Howell and Kimmel, 2008). The magnitude of amphetamine-
induced DA release in the ventral striatum has been positively
correlated with subjective experience of euphoria (Drevets
et al., 2001) and self-reported drug-wanting in humans (Leyton
et al., 2002). In this regard, the identification of TAAR1 as
a novel target for amphetamine and related drugs reveals a
previously unrecognized mechanism of action for stimulant
drugs and brings about a new opportunity for developing
efficacious anti-addiction agents. Studies using transfected cells
and rhesus monkey and mouse brain striatal synaptosomes
showed that methamphetamine activation of TAAR1 triggers a
series of cellular phosphorylation cascades, leading to reduced
DA uptake, enhanced DA eﬄux, and DAT internalization,
which partially contribute to the known DA-releasing effects
of methamphetamine (Xie and Miller, 2009a). These actions
of methamphetamine at TAAR1 suggest that pharmacological
modulation of TAAR1 may hold promise as a therapeutic
tool in methamphetamine addiction. Amphetamines possess
therapeutic value themselves although their abuse potential
strongly limits their long-term efficacy. Amphetamine is used as
a treatment for ADHD, which has been associated with impaired
monoaminergic modulation of prefrontal cortical function
(Bymaster et al., 2002; Arnsten, 2006) and for narcolepsy and
obesity, which are also associated with deficits in DA function
(Mefford et al., 1983; Mitler and Hajdukovic, 1991; Wang
et al., 2001; Geiger et al., 2009). The cognitive-enhancing,
anti-narcoleptic, and anorexigenic effects of amphetamine
have been attributed to its ability to increase monoamine
transmission (Nishino et al., 1997; Wang et al., 2001; Wisor
et al., 2001; Arnsten, 2006). The discovery that amphetamine-
like compounds activate TAAR1 raises the possibility that
TAAR1 may serve as target for therapeutic intervention
in these neurological and psychopathological conditions,
especially taking into consideration that TAAR1 can exert
direct control over DA function, as described in the preceding
sections.
Finally, an interesting finding is that several efficacious
ligands at TAAR1 are known as antagonists at biogenic
amine receptors or inhibitors of monoamine transporters.
For example, the adrenergic or serotonergic antagonists
phentolamine, tolazoline, and cyproheptadine, and the
non-substrate DA transporter inhibitors, nomifensine, and
1-methyl-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP), are all
agonists at TAAR1 (Bunzow et al., 2001). Consequently, the
identification of TAAR1 as an action site for these compounds
may complement our understanding of their better recognized
antagonistic effects at other GPCR or transporter proteins. By
contrast, cocaine, a DAT inhibitor and potent psychomotor
stimulant, exhibited low affinity at TAAR1 (Bunzow et al.,
2001).
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TAAR1 AND NEUROPSYCHIATRIC
DISORDERS
The implications of TAAR1 in neuropsychiatric disorders are
wide-ranging and are summarized inTable 1. PD is characterized
by a progressive degeneration of dopaminergic cells along
the nigrostriatal pathway and subsequent loss of DA in the
striatum (Lotharius and Brundin, 2002). L-DOPA treatment
remains the gold standard pharmacotherapy for PD due to
its ability to partially replenish striatal DA levels. However,
chronic L-DOPA treatment produces disabling motor side
effects such as dyskinesias and motor fluctuations (Lloyd et al.,
1975; Dauer and Przedborski, 2003). Given, the ability of
TAAR1 to downregulate DA transmission, medications that
suppress TAAR1 activation may hold promise for treating PD.
Supporting this hypothesis, the effectiveness of L-DOPA in
reducing parkinsonian symptoms was enhanced in TAAR1-
deficient mice compared to their wild-type counterparts
(Sotnikova et al., 2008). Moreover, upregulation of the β-
arrestin2 pathway has been associated with reduced levels of
L-DOPA-induced dyskinesia, with no concomitant decreases
in the therapeutic efficacy of L-DOPA (Urs et al., 2015).
As discussed above, this signaling pathway is modulated
by TAAR1, further strengthening the idea that TAAR1-
based pharmacotherapies might have implications for the
treatment of PD.
Several lines of evidence have implicated TAAR1 in the
etiology of psychosis. First, all human TAAR genes are tightly
clustered in a narrow region of 109 kb of chromosome 6q23.1
(Borowsky et al., 2001; Bunzow et al., 2001; Lindemann et al.,
2005), which is close to or among a few susceptible loci
that have been reproducibly associated with schizophrenia
(Straub et al., 1995; Cao et al., 1997; Lindholm et al., 1999)
and bipolar affective disorder (Rice et al., 1997; Dick et al.,
2003; Sklar et al., 2008) in linkage or association studies,
suggesting a possible causal role of this receptor family in
the etiology of psychosis/polygenic neuropsychiatric disorders.
Consistent with this notion, TAAR1 knock-out mice exhibited an
elevation of brain high-affinity D2s receptors and dopaminergic
supersensitivity (Wolinsky et al., 2007). In patients with
schizophrenia, increased availability and excessive stimulation of
D2s have been observed during a psychotic episode (Laruelle
et al., 1996; Abi-Dargham et al., 1998). Further, the effectiveness
of antipsychotics to occupy D2s has been linked to clinical
responsiveness and extrapyramidal side effects (Pickar, 1995;
Kapur et al., 2000; Seeman, 2011). Also, greater response to
DA stimulants, such as amphetamine and methylphenidate, has
been found in schizophrenics compared to healthy controls
(Seeman, 2011). These findings reveal common characteristics
of altered dopaminergic activity in TAAR1 deficient mice
and schizophrenia patients, suggesting that abnormal TAAR1
function may contribute to psychotic symptoms. In addition,
dysregulation of the β-arrestin2/AKT/GSK3β pathway has been
implicated in schizophrenia and a wide range of clinically
effective antipsychotics were shown to antagonize D2 receptor-
mediated β-arrestin2 signaling and inhibit GSK3β activity (Masri
et al., 2008; Beaulieu et al., 2009; Emamian, 2012; Urs et al.,
2012). Therefore, the finding that TAAR1 stimulation through
the β-arrestin2-dependent pathway leads to a silencing of
GSK3β adds further support for the involvement of TAAR1 in
schizophrenia and suggests that drugs that increase β-arrestin2
signaling by TAAR1 may be effective treatment for this disease.
In addition, a novel D-neuron hypothesis has recently emerged
proposing the implication of the TA system in the pathogenesis
of schizophrenia. D-neurons are non-monoaminergic AADC-
containing striatal cells, postulated to be TA-producing neurons
(Keiko, 2012; Ikemoto, 2013). According to this hypothesis,
decreased proliferation of neural stem cells in the subventricular
zone of the lateral ventricle leads to a reduction of striatal D-
neurons and thus insufficient TA synthesis. The ensuing decrease
in TAAR1 stimulation ultimately causes augmented DA release
in the NAc and striatal DA hyperstimulation further inhibits
the proliferation of the neural stem cells, further accentuating
DA hyperactivity (Ikemoto, 2015). However, this proposition
is mainly built upon the observation of reduced striatal D-
neurons in patients with schizophrenia (Ikemoto et al., 2003) and
requires further experimental support. Apart from dysfunctional
dopaminergic activity, reduced glutamatergic transmission has
also been proposed as a causal factor in schizophrenia,
particularly in relation to the negative symptoms and cognitive
impairment associated with the disease (Javitt, 2004; Coyle, 2006;
Goff and Coyle, 2014). The NMDA receptor antagonist, PCP,
has been widely used in rodent models of schizophrenia to
produce psychotic symptoms and some atypical antipsychotics
are known to modulate NMDA-mediated neurotransmission
(Jentsch and Roth, 1999; Goff and Coyle, 2014). Interestingly,
selective activation of TAAR1 by both full and partial agonists
has been shown to reverse glutamatergic hypofunction induced
by selective NMDA receptor antagonists in wild-type animals
and mutant mice with NMDA receptor deficiency (Revel
et al., 2011, 2012a, 2013), suggesting that TAAR1 activation
may enhance glutamatergic function. Moreover, TAAR1 KO
mice displayed altered subunit composition of cortical NMDA
receptors and dysregulation of NMDA receptor-dependent
synaptic function, accompanied by increased perseveration and
impulsivity. Moreover, full and partial activation of TAAR1 by
specific agonists reduced impulsive behaviors in normal mice,
suggesting a facilitating role of TAAR1 on cortical glutamate
transmission and associated behavioral functions (Espinoza
et al., 2015). In addition, TAAR1 KO exhibited significant
deficits in sensorimotor gating measured as impaired prepulse
inhibition of acoustic startle (Wolinsky et al., 2007), which is a
known behavioral signature in schizophrenia regulated by both
dopaminergic and glutamatergic mechanisms (Wan et al., 1995;
Wan and Swerdlow, 1996; Geyer et al., 2001). Also, the selective
full and partial TAAR1 agonists, RO5256390 and RO5263397,
respectively, produced a brain activation pattern akin to that
induced by the antipsychotic drug, olanzapine (Revel et al., 2013).
Together, these data persuasively implicate TAAR1 in the etiology
and neuropathology of psychosis, and support the investigation
of TAAR1-based pharmacological tools as treatments for this
condition.
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TABLE 1 | Implications of TAAR1 in major neurological diseases and psychopathological disorders.
Neurological
conditions
Major findings Studies Implication
Parkinson’s
disease (PD)
1. Therapeutic effectiveness of L-DOPA was enhanced
in TAAR1-deficient mice
Sotnikova et al., 2008 TAAR1 antagonists or partial agonist may aid in L-DOPA
treatment for PD
2. β-arrestin 2 pathway signaling is associated with
reduced L-DOPA-induced dyskinesia; TAAR1
activation modulates this pathway
Espinoza et al., 2015;
Harmeier et al., 2015; Urs
et al., 2015
Psychosis 1. All human TAAR genes are clustered in a
chromosome region associated with bipolar disorder
and schizophrenia
Borowsky et al., 2001;
Bunzow et al., 2001
TAAR1 deficiency may contribute to the etiology and
neuropathology of psychosis, in particular schizophrenia.
TAAR1 agonists may be effective in alleviating psychotic
symptomatology2. TAAR1 KO mice had elevated brain high-affinity D2s
receptors and showed dopaminergic supersensitivity,
resembling patients with schizophrenia
Wolinsky et al., 2007
3. Patients with schizophrenia showed reduced striatal
D-neurons, which might lead to reduced TA synthesis
and decreased TAAR1 stimulation
Ikemoto et al., 2003
4. TAAR1 KO mice showed altered structure and
function of cortical NMDA receptors, accompanied
with behavioral perseveration and impulsivity; TAAR1
full, and partial agonists reversed pharmacologically- or
genetically-induced glutamatergic hypofunction and
reduced impulsivity in normal mice, consistent with a
hypoglutamatergic hypothesis of schizophrenia
Revel et al., 2011, 2012b,
2013; Espinoza et al., 2015
5. TAAR1 KO mice had impaired sensorimotor gating,
a key characteristic of schizophrenia reflecting
dysfunction of dopaminergic and glutamatergic
pathways
Wolinsky et al., 2007
6. TAAR1 agonists produced brain activation patterns
similar to those elicited by olanzapine in rodents
Revel et al., 2013
7. Increased signaling of GSK3β has been linked to
schizophrenia, while TAAR1 interacts with D2
receptors to shift β-arrestin 2 recruitment from D2
receptor to TAAR1, resulting in reduced GSK3β activity
Harmeier et al., 2015
Drug
addiction
1. TAAR1 KO mice had elevated spontaneous firing
rate of midbrain DA neurons and increased
extracellular DA in the NAc. They also showed
enhanced sensitivity to the monoamine-releasing and
locomotor-stimulating effects of amphetamine and
MDMA, and to methamphetamine-induced
conditioned place preference
Wolinsky et al., 2007;
Lindemann et al., 2008; Di
Cara et al., 2011; Leo et al.,
2014; Achat-Mendes et al.,
2012
TAAR1 is constitutively active or tonically activated by
ambient levels of amines and controls DA activity, therefore
TAAR1 activation level by full or partial agonists may
regulate the up and downs of the DA system during the
addiction cycle. Moreover, both partial and full activation of
TAAR1 is effective in reducing abuse-related behavioral and
neurochemical effects of cocaine and methamphetamine,
supporting TAAR1-based pharmacotherapy in addiction2. While TAAR1 full agonists reduced the firing
frequency of midbrain DA neurons in mice brain slices,
a TAAR1 antagonist and TAAR1 partial agonists
increased it
Bradaia et al., 2009; Revel
et al., 2011, 2012b, 2013
3. A TAAR1 full agonist reduced electrically evoked DA
release in the dorsal striatum and NAc in mice brain
slices whereas a TAAR1 antagonist increased NAc DA
release
Leo et al., 2014
4. TAAR1 partial agonists prevented cocaine-induced
DA overflow and transiently blocked
methamphetamine-evoked DA accumulation in the
NAc of rats
Pei et al., 2014; Cotter et al.,
2015
5. In rodents, selective TAAR1 partial and full agonists
reduced amphetamine- and cocaine-induced
hyperlocomotion; decreased cocaine-induced
behavioral sensitization, conditioned place preference,
self-administration, the motivation to take cocaine, and
relapse of cocaine seeking; downwardly shifted full
dose-response curve for cocaine self-administration;
and prevented cocaine-induced potentiation of brain
reward function
Revel et al., 2011, 2012b,
2013; Thorn et al., 2014; Pei
et al., 2014, 2015
(Continued)
Frontiers in Neuroscience | www.frontiersin.org 10 April 2016 | Volume 10 | Article 148
Pei et al. TAAR1 Neuropharmacology and Neuropsychiatry
TABLE 1 | Continued
Neurological
conditions
Major findings Studies Implication
6. In rodents, TAAR1 partial agonists reduced
methamphetamine-induced behavioral sensitization,
self-administration, and relapse of methamphetamine
seeking
Jing et al., 2014; Cotter
et al., 2015
Affective
disorder
1. TAAR1 agonists enhanced performance in
differential reinforcement of low-rate behavioral
paradigm in monkeys and reduced immobility time in
forced-swim test in rats
Revel et al., 2012b, 2013 TAAR1 may constitute a novel target for medicinal
development for depression and anxiety disorders
2. TAAR1 agonists prevented stress-induced
hyperthermia in mice, indicating anxiolytic effects
Revel et al., 2011, 2012b
Others 1. TAAR1 partial and full agonists improved response
accuracy in object retrieval task in monkeys and
reduced PCP-induced decline in attentional set-shifting
in rats
Revel et al., 2012b, 2013 TAAR1-based ligands may have wider benefits beyond
disease conditions, such as enhancing cognition and
wakefulness
2. In monkeys, selective TAAR1 agonist increased
wakefulness, with a potency similar to caffeine, but did
not have caffeine-related side effects
Revel et al., 2012b, 2013
One of the best documented findings in TAAR1 pharmacology
is the ability of this receptor to regulate the neurochemical and
behavioral actions of psychomotor stimulant drugs, which has
fuelled the notion that TAAR1-selective compounds could have
therapeutic value in addiction treatment. Psychostimulant drugs
exert their effects in the CNSmainly by causing strong alterations
in DA transmission and long-lasting neuroadaptations in
the dopaminergic system (Volkow et al., 1999; Grace, 2000;
Pierce and Kumaresan, 2006). Indeed, the close anatomical
and functional interaction of TAAR1 with the DA system
and the documented role of TAs in brain reward and
reinforcement functions are consistent with this hypothesis.
Moreover, as discussed in the previous sections, studies with
transgenic mice and selective agonists at TAAR1 have provided
compelling demonstration of TAAR1’s ability to downregulate
the monoaminergic response to psychomotor stimulants. Several
recent studies have been aimed at investigating the therapeutic
potential of TAAR1 agonists in well-validated animal models
of drug addiction. Revel and collaborators provided the first
evidence that the partial agonist, RO5203648, decreased cocaine-
induced locomotor activity and self-administration in rats
(Revel et al., 2012b). Subsequent work revealed that the partial
and full agonists, RO5203648 and RO5256390, respectively,
both produced downward shifts in the dose-response curve
for cocaine self-administration and prevented cocaine-induced
lowering of ICSS thresholds (Pei et al., 2015), indicating
that partial or full TAAR1 activation blocks the reinforcing
properties of cocaine. In agreement with these observations,
another TAAR1 partial agonist, RO5263397, reduced cocaine-
induced behavioral sensitization and cocaine conditioned place
preference (Thorn et al., 2014). Importantly, TAAR1 agonists
also prevented context-induced cocaine relapse and cue- and
cocaine prime-induced reinstatement of cocaine seeking (Pei
et al., 2014; Thorn et al., 2014). In the case of methamphetamine,
the partial agonists, RO5203648, and RO5263397, reduced
methamphetamine-induced behavioral sensitization, and self-
administration (Jing et al., 2014; Cotter et al., 2015). RO5263397
also blocked cue- and drug prime-induced reinstatement of
methamphetamine seeking (Jing et al., 2014). Remarkably, at
doses that were effective at attenuating drug-related behaviors,
such as drug relapse and reinstatement, these agonists did not
suppress responding maintained by natural reinforcers, ruling
out non-specific effects of TAAR1 agonists on general motoric
and motivational functions (Pei et al., 2014; Cotter et al., 2015).
In fact, using a progressive ratio schedule of reinforcement,
the partial agonist, RO5203648, decreased the break point
for cocaine self-administration but enhanced responding for
food (Pei et al., 2014), suggesting clearly dissociable effects of
TAAR1 activation on drug- and food-maintained responding.
Although, the mechanisms by which TAAR1 activation decreases
motor stimulant effects are not well-understood, using fast-
scan cyclic voltammetry we have shown previously that
activation of TAAR1 with the partial agonist, RO5203648,
prevented the potentiation of DA transmission caused by
cocaine in the NAc without affecting DA uptake kinetics. This
suggests that the TAAR1 agonist attenuated cocaine-stimulated
DA overflow by mechanisms other than direct interference
with DA uptake (Pei et al., 2014). Together, these findings
demonstrate that TAAR1 agonists are effective at modulating the
neurochemical and behavioral effects of psychomotor stimulants
and lend strong support to the development of medications
targeting TAAR1 as treatments for psychostimulant addiction.
Furthermore, other classes of abused substances such as opiates,
ethanol, cannabinoids, and nicotine all have been shown to
directly or indirectly influence DA transmission. Although, DA-
independent processes are also implicated in the psychoactive
actions of addictive drugs (Tanda et al., 1997; Pierce and
Kumaresan, 2006; Hiranita et al., 2013; Söderpalm and Ericson,
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2013), the ability of TAAR1 to modulate DA transmission still
strongly raises the intriguing possibility that the TAAR-based
approach will form a new generation of medications for addictive
disorders.
TAAR1 may also play a crucial role in emotional regulation
given that TAAR1 expression is enriched in the amygdala
(Borowsky et al., 2001), a key integrative region for emotions,
emotional behavior, and motivation (Phelps and LeDoux, 2005).
The association between TA deficiency and affective disorders,
such as depression, suggests that TAAR1 activation may serve
to stabilize maladaptive mood and emotional fluctuations and
contribute to the effects of antidepressants or anxiolytics. In
support of this hypothesis, TAAR1 agonists were shown to
enhance performance in a differential reinforcement of low-
rate behavioral paradigm in monkeys, reduce immobility time
in a forced-swim test in the rat, and prevent stress-induced
hyperthermia in mice, thus demonstrating anti-depressant and
anxiolytic properties (Revel et al., 2011, 2012a, 2013).
Recent evidence indicates that pharmacological manipulation
of TAAR1 could have wider applications to encompass not
only disease treatment but also mental health promotion.
TAAR1 selective ligands have been shown to enhance cognition
and increase wakefulness (Revel et al., 2011, 2012a, 2013).
Several selective full and partial agonists at TAAR1 improved
response accuracy in an object retrieval task in monkeys and
rescued PCP-induced decline in attentional set-shifting in the
rat, demonstrating pro-cognitive effects including increased
attention, adaptive response inhibition, and cognitive flexibility
(Revel et al., 2012a, 2013). Also, two selective TAAR1 partial
agonists increased wakefulness in a manner similar to caffeine
without eliciting caffeine-associated side effects such as increased
locomotion and changes in core body temperature (Revel et al.,
2012a, 2013). Collectively, these findings suggest that TAAR1
pharmacologymay have implications for cognitive enhancement,
sleep control, and mental health advancement in a broader
context that concerns workplace performance and general well-
being.
CONCLUSIONS
The novel findings discussed in this review uncover the pivotal
role of TAs and their associated receptors in the functional
regulation of classical aminergic systems and highlight the
relevance of TAAR1 as a molecular target to engineer innovative
forms of treatment for neurological disease. Although, the
physiological significance of TAs was not fully recognized
until the discovery of their receptor family, TAs have long
been associated with the classical amines. Neuropharmacological
research into TAAR1, being the only member of the TAAR
family that is phylogenetically conserved inmammals, has gained
considerable momentum over the past decade, largely fuelled by
the development of specific tools to unveil its neurophysiological
and behavioral functions, most notably transgenic models,
and direct ligands. TAAR1 interacts with the DAT and DA
D2 receptors, modulates DA neuron firing rate and DA
release, regulates the biochemical signaling cascades triggered
by amphetamine-like psychostimulants and, when selectively
deleted or activated, has the remarkable ability to influence key
behaviors associated with neurological dysfunction. As a result,
there is growing interest in developing TAAR1-based therapies
for the treatment of a range of neuropsychiatric disorders,
including PD, psychosis, drug addiction, and mood disorders.
Besides, the demonstrated wake-promoting and cognitive-
enhancing properties of TAAR1 agonists may provide a platform
for the design of complementary interventions for other forms
of maladaptive behaviors. However, our understanding of the
underlying mechanisms by which TAAR1 is able to exert
such notable regulatory effects remains scant and future efforts
should be devoted to fully elucidate the molecular pathways
and downstream targets that are recruited by TAAR1 under
a variety of physiological and non-physiological conditions.
Moreover, the development of more refined research tools
such as TAAR1 agonists and antagonists, particularly the latter,
with enhanced pharmacokinetic/dynamic profile will allow more
effective assessment of TAAR1 as a molecular target for the
development of therapeutics in neuropsychiatry. Despite, these
limitations, compelling evidence now links TAs and TAAR1 to
neuropsychiatric disorders and, as further knowledge is unveiled
and better research tools become available to study TAAR1,
we can look forward to a new era of basic and translational
neuroscience research.
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